Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Erratum to: Invest New Drugs

DOI 10.1007/s10637-013-9953-8

Following online publication of this article, some factual and typographical errors have been identified; the correct details are as follows: In the results section (safety subsection), the rate of leukopenia was 27 % (not 33 %), and four patients experienced grade 3 lymphopenia (not five patients). In the efficacy subsection, the duration of response should be 10.4 months (not 10.5 months). In Table 2, the rate of any-grade proteinuria should be 80 % (not 8 %). In Table 4, the AUC0–24 for the M5 metabolite should be 380.0 (164.2) μg.h/L (not 380.5/164.2(112.0)).